| Literature DB >> 22986922 |
Wei Fang1, Fan Peng, Tao Yi, Cong Zhang, Chunxi Wan, Huibi Xu, Christopher Waikei Lam, Xiangliang Yang.
Abstract
The commercial preparation named “Tripterygium glycosides” prepared by column chromatography has been used for the treatment of inflammatory and autoimmune diseases with significant efficacy but concurrent toxicity. The aim of this study was to reduce the toxicity of Tripterygium extracts, using cytotoxicity and anti-inflammatory activity of the three principal active components of Tripterygium wilfordii Hook. F. (TWHF)as guiding parameters. Column chromatography was replaced by sodium carbonate extraction for removing the acidic compounds and enriching epoxyditerpenoids and alkaloids in the extract. Results showed that the therapeutic index (IC50/EC50) on murine macrophage Raw 264.7 cells and rat mesangial HBZY-1 cells of the extract prepared by sodium carbonate extraction was significantly higher than that of Tripterygium glycosides(0.8 and 5.2 vs. 0.3 and 2.6, p < 0.05), while its cytotoxicity on human liver HL7702 cells was significantly lower (14.5 ± 1.4 vs. 6.8 ± 0.9, p < 0.05). Further acute oral toxicity experiments showed that the LD50 value of this extract was 1,210 mg/kg compared to 257 mg/kg for Tripterygium glycosides. All the above results suggest that Tripterygium extract prepared by sodium carbonate extraction may represent a potentially optimal source of medicine with good therapeutic index.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22986922 PMCID: PMC6268481 DOI: 10.3390/molecules170911113
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Cytotoxicity and anti-inflammatory activity of triptolide, celastrol and wilforine.
| Sample | HBZY-1 cells | IC50/EC50 | RAW264.7 cells | IC50/EC50 | ||
|---|---|---|---|---|---|---|
| Cytotoxicity IC50 (nmol/L) | Anti-inflammatory activity EC50 (nmol/L) | Cytotoxicity IC50 (nmol/L) | Anti-inflammatory activity EC50 (nmol/L) | |||
| Triptolide | 230.3 ± 9.9 | 20.7 ± 2.1 | 11.1 | 40.2 ± 2.7 | 25.0 ± 4.4 | 1.6 |
| Celastrol | 3715 ± 342 | 1040 ± 40 | 3.6 | 360 ± 41 | 260.3 ± 20.9 | 1.4 |
| Wilforine | nd | nd | nd | nd | nd | nd |
nd = not detected.
Weights and contents of celastrol, triptolide and wilforine in different extracts.
| Sample | Content (%) of active compound | Weight (mg) | ||
|---|---|---|---|---|
| triptolide | celastrol | wilforine | ||
| Ethanol extract | 0.015 | 0.7 | 1.1 | 1,000.0 |
| EtOAc extract | 0.032 | 1.4 | 2.4 | 454.5 ** |
| Extract 1 | 0.051 | 0.09 | 4.4 | 234.0 ** |
| Extract 2 | nd * | 2.4 | nd | 184.6 ** |
| 0.92 | nd * | 1.7 | - | |
* not detected; ** Based on the starting weight of ethanol extract at 1,000.0 mg.
Cytotoxic and anti-inflammatory activities of different extracts.
| Sample | HBZY-1 cells | RAW264.7 cells | HL7702 cells | ||||
|---|---|---|---|---|---|---|---|
| Cytotoxicity IC50 (μg/mL) | Anti-inflammatory activity EC50 (μg/mL) | IC50/EC50 | Cytotoxicity IC50 (μg/mL) | Anti-inflammatory activity EC50 (μg/mL) | IC50/EC50 | Cytotoxicity IC50 (μg/mL) | |
| EtOAc Extract | 7.3 ± 1.1 | 1.3 ± 0.2 | 5.6 | 1.2 ± 0.3 | 2.3 ± 0.9 | 0.5 | 4.9 ± 0.3 |
| Extract 1 | 12.5 ± 2.0 * | 2.4 ± 0.3 * | 5.2 | 5.3 ± 0.4 *,# | 6.6 ± 0.3 *,# | 0.8 | 14.5 ± 1.4 *,# |
| Extract 2 | 11.7 ± 1.8 * | 2.7 ± 0.6 * | 4.3 | 1.7 ± 0.2 | 2.0 ± 1.0 | 0.85 | 33.3 ± 0.2 * |
| 4.0 ± 0.2 | 1.5 ± 0.3 | 2.6 | 1.7 ± 0.5 | 5.3 ± 0.6 * | 0.3 | 6.8 ± 0.9 | |
Compared to EtOAc extract: * p < 0.05, Compared to Extract 2: #p < 0.05.
Figure 1Protocol for preparation of different TWHF extracts.